Pulmonx (LUNG) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Pulmonx (LUNG) over the past year, gaining 42.9% versus a gain of 1.7%. Over five years, LUNG leads with a -95.5% price change compared with -97.8% for PYPD. PolyPid is the larger company by market cap ($102.9 million vs $78.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | PYPD |
|---|---|---|
| Share price | $1.83 | $5.07 |
| Market cap | $78.60M | $102.88M |
| 1-day change | +1.10% | +3.37% |
| YTD return | -18.10% | +12.90% |
| 1-year return | +1.69% | +42.86% |
| 5-year return | -95.45% | -97.83% |
| EPS (TTM) | $-1.15 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.89 | $5.73 |
| 52-week low | $1.13 | $3.06 |
| Distance from 52-week high | -36.68% | -11.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +85.79% | +131.98% |
| Average volume | 477.26K | 176.73K |
| Shares outstanding | 42.95M | 20.31M |
| Employees | 296 | 69 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed LUNG by 41.2 percentage points over the past year.
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
LUNG vs PYPD FAQ
Which is bigger, Pulmonx or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $102.88M compared with $78.60M for Pulmonx (LUNG).
Which stock has performed better over the past year, LUNG or PYPD?
PYPD returned +42.86% over the past 12 months, compared with +1.69% for LUNG (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and PolyPid in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.